• Hrvoje Roguljić, Jerko Arambašić, Vjera Ninčević, Lucija Kuna, Igor Šesto, Ashraf Tabll, Robert Smolić, Aleksandar Včev, Dragan Primorac, George Y Wu, and Martina Smolić.
• Martina Smolić, Department of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Crkvena 21, 31000 Osijek, Croatia, martina.smolic@fdmz.hr.
• Croat. Med. J. 2022 Jun 22; 63 (3): 287294287-294.

AbstractIn patients with COVID-19, thromboinflammation is one of the main causes of morbidity and mortality, which makes anticoagulation an integral part of treatment. However, pharmacodynamic and pharmacokinetic properties of direct oral anticoagulants (DOACs) limit the use of this class of anticoagulants in COVID-19 patients due to a significant interference with antiviral agents. DOACs use in COVID-19 hospitalized patients is currently not recommended. Furthermore, patients already on oral anticoagulant drugs should be switched to heparin at hospital admission. Nevertheless, outpatients with a confirmed diagnosis of COVID-19 are recommended to continue prior DOAC therapy. More studies are required to clarify the pathogenesis of COVID-19-induced derangement of the coagulation system in order to recommend an appropriate anticoagulant treatment.

13 keywords...

hide…